WO2008039984A3 - Methods and compositions for treating conditions by inhibiting cathepsin d - Google Patents

Methods and compositions for treating conditions by inhibiting cathepsin d Download PDF

Info

Publication number
WO2008039984A3
WO2008039984A3 PCT/US2007/079891 US2007079891W WO2008039984A3 WO 2008039984 A3 WO2008039984 A3 WO 2008039984A3 US 2007079891 W US2007079891 W US 2007079891W WO 2008039984 A3 WO2008039984 A3 WO 2008039984A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating conditions
inhibiting cathepsin
cathepsin
Prior art date
Application number
PCT/US2007/079891
Other languages
French (fr)
Other versions
WO2008039984A2 (en
Inventor
Valerie Anne Ingrid Natale
Neal Caldecott
Original Assignee
Obura Company
Valerie Anne Ingrid Natale
Neal Caldecott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obura Company, Valerie Anne Ingrid Natale, Neal Caldecott filed Critical Obura Company
Publication of WO2008039984A2 publication Critical patent/WO2008039984A2/en
Publication of WO2008039984A3 publication Critical patent/WO2008039984A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ABSTRACT This invention relates to compounds that are cathepsin D inhibitors and pharmaceutical compositions containing them. The compounds of the invention have neurotrophic activity and are useful in the treatment and prevention of neuronal disorders such as amyotrophic lateral sclerosis, multiple sclerosis, and muscular dystrophy.
PCT/US2007/079891 2006-09-28 2007-09-28 Methods and compositions for treating conditions by inhibiting cathepsin d WO2008039984A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82739206P 2006-09-28 2006-09-28
US60/827,392 2006-09-28

Publications (2)

Publication Number Publication Date
WO2008039984A2 WO2008039984A2 (en) 2008-04-03
WO2008039984A3 true WO2008039984A3 (en) 2008-08-21

Family

ID=39231012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079891 WO2008039984A2 (en) 2006-09-28 2007-09-28 Methods and compositions for treating conditions by inhibiting cathepsin d

Country Status (1)

Country Link
WO (1) WO2008039984A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012164234A1 (en) * 2011-05-27 2012-12-06 Md Pharma Ab Novel treatments
WO2014084430A1 (en) * 2012-11-30 2014-06-05 경상대학교 산학협력단 Combination anti-cancer therapy
IT202000012370A1 (en) * 2020-05-26 2021-11-26 Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L COMPOSITION INCLUDING PEPSTATIN AND ALGINIC ACID OR A SALT HEREBY AND ITS USE
WO2024175592A1 (en) * 2023-02-21 2024-08-29 Université De Strasbourg Peptide inhibitors of cathepsin d/lrp-1 interaction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042000A1 (en) * 2003-10-23 2005-05-12 Neuren Pharmaceuticals Limited Neuroprotective effects of gly-pro-glu following intravenous infusion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042000A1 (en) * 2003-10-23 2005-05-12 Neuren Pharmaceuticals Limited Neuroprotective effects of gly-pro-glu following intravenous infusion

Also Published As

Publication number Publication date
WO2008039984A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
WO2007087250A3 (en) Tricyclic inhibitors of 5-lipoxygenase
WO2006091395A3 (en) Inhibitors of akt activity
WO2008070041A3 (en) Inhibitors of akt activity
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2008033562A3 (en) Kinase inhibitor compounds
WO2006135627A3 (en) Inhibitors of akt activity
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2006110638A3 (en) Inhibitors of akt activity
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007139967A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139955A8 (en) Triazole compounds that modulate hsp90 activity
WO2007139968A3 (en) Triazole compounds that modulate hsp90 activity
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843485

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843485

Country of ref document: EP

Kind code of ref document: A2